Trial intelligence / Profile preview

Dasatinib in imatinib-resistant or intolerant CML and Ph+ ALL (Phase II, China)

CTR20131053Phase 2Active

Sponsor

Bristol Myers Squibb

Start

Feb 2014

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1